Jump to content
Wikipedia The Free Encyclopedia

Sinopharm Group

From Wikipedia, the free encyclopedia
Chinese biotechnology company
Not to be confused with Sinopharm, the short name of the parent company China National Pharmaceutical Group.
Sinopharm Group
logo of Sinopharm Group (same as China National Pharmaceutical Group), with bilingual name on the right
logo of Sinopharm Group (same as China National Pharmaceutical Group), with bilingual name on the right
Company typepublic
unlisted (A share)
SEHK: 1099 (H share)
ISIN CNE100000FN7
IndustryPharmaceutical
Founded
  • 1998 (predecessor)
  • 2003
FounderChina National Pharmaceutical Group
HeadquartersSinopharm Plaza, ,
China
Area served
China
Key people
  • Wei Yulin (Chairman)
  • Chen Qiyu (Vice-Chairman)
  • Li Zhiming (President)
RevenueIncrease CN227円.069 billion (2015)
Increase CN9円.169 billion (2015)
Increase CN3円.761 billion (2015)
Total assets Increase CN138円.267 billion (2015)
Total equity Increase CN30円.052 billion (2015)
OwnerSinopharm Industrial Investment (56.79%)
Parent Sinopharm Industrial Investment
Subsidiaries Sinopharm CNMC
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards[1]
Sinopharm Group Co., Ltd.
Simplified Chinese 国药控股股份有限公司
Traditional Chinese 國藥控股股份有限公司
Literal meaningSinopharm Holding Joint-Stock Limited Company
Transcriptions
Sinopharm Group
Simplified Chinese 国药控股
Traditional Chinese 國藥控股
Literal meaningSinopharm Holding
Transcriptions
Second alternative Chinese name
Simplified Chinese 国控股份有限公司
Traditional Chinese 國控股份有限公司
Transcriptions

Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

Its H shares were listed on the Hong Kong Stock Exchange in 2009,[2] with its IPO price of HK16ドル per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.

Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list.[3]

COVID-19 Vaccine development

[edit ]

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[4] the Sinopharm COVID-19 vaccine,[5] or BIBP vaccine,[5] [6] [7] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[8] The BIBP vaccine shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19.[9]

Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the BIBP vaccine is 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[10] In December 2020, the UAE previously announced interim results showing 86% efficacy.[11] While mRNA vaccines showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[12]

The BIBP vaccine is being used in vaccination campaigns by certain countries in Asia,[13] [14] [15] Africa,[16] [17] [18] South America,[19] [20] [21] and Europe.[22] [23] [24] Sinopharm was expected to produce one billion doses of the BIBP vaccine in 2021.[25] On 7 May 2021, the World Health Organization approved the vaccine for use in COVAX.[14] [26]

See also

[edit ]

References

[edit ]
  1. ^ "2015 Annual Report" (PDF). Sinopharm Group. Hong Kong Stock Exchange. 25 April 2016. Retrieved 22 November 2016.
  2. ^ "China's Sinopharm gets OK for 1ドル bln HK IPO". Reuters. 2009年07月29日. Retrieved 2020年11月14日.
  3. ^ "Sinopharm Group". Forbes. Retrieved 2020年11月14日.
  4. ^ Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. (January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304 . PMID 33069281.
  5. ^ a b "The Sinopharm COVID-19 vaccine: What you need to know". World Health Organization. 10 May 2021. Retrieved 5 July 2021.
  6. ^ Nguyen S (5 June 2021). "Coronavirus: Vietnam approves Sinopharm's vaccine, but will people take it?". South China Morning Post. Retrieved 5 July 2021.
  7. ^ Lahiri T, Li J (16 June 2021). "What we now know about the efficacy of China's Covid-19 vaccines". Quartz. Retrieved 5 July 2021.
  8. ^ "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. 2020年11月19日. Retrieved 2020年12月09日.
  9. ^ Corum, Jonathan; Zimmer, Carl (2021年04月26日). "How the Sinopharm Vaccine Works". The New York Times. ISSN 0362-4331 . Retrieved 2021年04月29日.
  10. ^ Kaabi, Nawal Al; Zhang, Yuntao; Xia, Shengli; et al. (May 26, 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565 . PMC 8156175 . PMID 34037666.
  11. ^ "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. 9 December 2020. Retrieved 2020年12月13日.
  12. ^ "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020年12月09日. Retrieved 2020年12月09日.
  13. ^ Liu R (2020年12月31日). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 2020年12月31日.
  14. ^ a b Turak, Natasha (2021年01月18日). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 2021年01月21日.
  15. ^ Dawn.com (2021年02月02日). "PM Imran kicks off Pakistan's Covid-19 vaccination drive". DAWN.COM. Retrieved 2021年02月03日.
  16. ^ "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters . 2021年01月24日. Retrieved 2021年01月24日.
  17. ^ Dumpis, Toms (2021年01月27日). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 2021年01月28日.
  18. ^ "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 2021年02月18日. Retrieved 2021年02月20日.
  19. ^ "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. 25 March 2021. Retrieved 2021年03月26日.
  20. ^ Aquino, Marco (2021年02月10日). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 2021年02月10日.
  21. ^ "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 2021年02月28日.
  22. ^ "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". Radio Free Europe/Radio Liberty. 20 January 2021. Retrieved 2021年01月21日.
  23. ^ "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 2021年02月24日. Retrieved 2021年02月26日.
  24. ^ "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 2021年03月15日. Retrieved 2021年03月16日.
  25. ^ "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 2021年02月05日. Retrieved 2021年02月28日.
  26. ^ Taylor, Adam (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post . Retrieved 7 May 2021.
[edit ]
Hong Kong Constituents of Hang Seng Index
Finance
Utilities
Properties
Commerce
and
Industry

AltStyle によって変換されたページ (->オリジナル) /